We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Graft-Stent Preferred for Thoracic Aorta Repair

By HospiMedica staff writers
Posted on 02 Apr 2007
A new study has shown that stent-graft repair of an injured or diseased thoracic aorta offered patients less risk of paraplegia as well as lower morbidity and mortality rates when compared to surgery. More...


Researchers at Guys Hospital (London, England) examined a prospective database from 1997 to 2006 that involved 190 patients (127 men and 63 women) who underwent nonsurgical thoracic aorta repair. All patients had diseased aortas in the thoracic area, such as degenerative aneurysm, dissections, ulcer, and other pathology. In total, 128 patients were treated electively and 62 underwent urgent repair. The stent-grafts were successfully deployed in 99.5% of the cases, and the incidence of death and permanent paralysis was only 1.6%. The study was presented at the Society of Interventional Radiology's 32nd annual scientific meeting, held during March 2007 in Seattle (WA, USA).

"Repairing a thoracic aorta should primarily be done with a stent-graft. Compared to surgery, the interventional treatment has a much lower risk of paralysis, less than 2% compared to open surgery which has approximately a 10% risk, even in the best of hands,” said lead author interventional radiologist John Reidy, M.D. "Placing a stent-graft is minimally invasive and much less traumatic for the patient. They avoid general anesthesia and have less problems with infection because there is no large chest incision.”

During surgical repair the patient is at increased risk of paraplegia because the thoracic aorta is clamped, cutting off blood to the spinal column. The interventional radiology treatment does not interrupt the blood supply since the endograft is advanced inside the artery, using imaging to guide it from the femoral artery in the groin to the precise location in the aorta where it is deployed, creating a new wall in the aorta from the inside.


Related Links:
Guys Hospital

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.